Erika Rickel
About Erika Rickel
Erika Rickel is a scientist at Bristol-Myers Squibb in the Greater Seattle Area with extensive experience in biochemical and immunological assays, drug development, and molecular biology.
Current Position at Bristol-Myers Squibb
Erika Rickel currently works as a Scientist at Bristol-Myers Squibb in the Greater Seattle Area. In her role, she focuses on the research and analysis of molecular markers of CAR T cell function and health. She brings her extensive experience in biochemical and immunological assays to the team, contributing significantly to the advancement of drug development projects.
Previous Roles in Biotechnology and Research
Erika Rickel has held various positions in the biotechnology and research field, demonstrating her broad expertise over the years. These roles include a stint as a Senior Associate Scientist at Celgene in 2019, a four-year tenure as a Scientist at Alpine Immune Sciences from 2015 to 2019, and a Researcher position at OncoSec Medical Inc in 2015. She has also worked as a Scientist and Senior Associate Scientist at Amgen from 2007 to 2014, showcasing her steady progression in the field.
Educational Background in Molecular Biology
Erika Rickel studied at the University of California, San Diego, where she earned a Bachelor of Science degree in Molecular Biology from 1990 to 1994. Her educational background laid a strong foundation for her research career in molecular biology and biotechnology.
Expertise in Biochemical and Immunological Assays
Erika Rickel is highly skilled in designing, performing, troubleshooting, and analyzing various biochemical and immunological assays. Her expertise includes RNA/DNA/protein isolation, qPCR, TaqMan, Bioinformatics analysis (Nanostring, Nextgen Sequencing), Multi-color FACS, ELISA, viral transduction, and mammalian cell culture (both primary cells and cell lines).
Experiences in Drug Development and Screening Assays
Erika Rickel has an impressive track record in the implementation and optimization of in vitro and ex vivo screening assays. Her work spans multiple phases of drug development, contributing to the advancement of new therapeutic agents. She has shown strong organizational skills and the ability to prioritize competing priorities in a fast-paced environment, aiding numerous research projects.